A B S T R A C T Cholic acid biosynthesis is defective in individuals with cerebrotendinous xanthomatosis (CTX) and is associated with the excretion of 5,8-cholestane-3a,7a, 12a,25-tetrol, an 
In the in vivo experiments, each one of the labeled precursors was administered intravenously to two CTX and two control subjects. In the controls, 5,8-[7,(-3H] cholestane-3a,7a,12a-triol as well as 5,8-[24-14C]-cholestane-3a,7a,12a,24S,25-pentol were rapidly converted to labeled cholic acid. Maximum specific activity values were reached within 1 d after pulse labeling, followed by exponential decay of the cholic acid specific activity curves. In contrast, these two precursors differed widely when administered to two CTX patients. While 5j8-[24-'4C]cholestane-3a,7a,12a, 24S,25-pentol was rapidly converted to [24-'4C]cholic acid and yielded identical decay curves with those obtained in the control subjects, maximum specific activity values in [7/3-3H] In the in vitro experiments, three enzymes on the 25-hydroxylation pathway of cholic acid were examined in both control and CTX subjects. The rate of the 25- hydroxylation of 5,3-cholestane-3a,7a,12a-triol in CTX INTRODUCTION Cholesterol is the obligatory precursor of bile acids in all vertebrates (1) . In the last few years, considerable information has been accumulated concerning the biosynthetic mechanisms whereby the weakly polar molecule ofcholesterol is transformed into the strongly polar bile acid molecule. The liver appears to be the sole organ capable of transforming cholesterol into bile acids. In man, the primary bile acids, i.e., those formed directly from cholesterol in the liver, are chenodeoxycholic acid and cholic acid.' The most commonly accepted mechanism whereby cholesterol is converted to cholic acid involves 26-hydroxylated intermediates, and 5f3-cholestane-3a,7a,12a,26-tetrol and 3a,7a,12a-trihydroxy5,8-cholestanoic acid are postulated as key intermediates in this biosynthetic pathway (2 Cofactors. NAD, NADP, NADPH, D-glucose-6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Calbiochem, San Diego, Calif.
Gas-liquid chromatography. The bile acids and bile alcohols were analyzed as the trimethylsilyl ether derivatives on 180 x 4-mm columns packed with 3% methylfluoroalkyl silicone on 80-100 mesh GAS Chrom Q (Ap- Defective Cholic Acid Synthesis in Cerebrotendinous Xanthomatosis plied Science Labs. Inc., State College, Pa.) column temperature 230°C (gas chromatograph, model 7610, Hewlett-Packard Co., Palo Alto, Calif.) (10) . Mass spectra. Mass spectra of the bile alcohols were obtained with a Varian MAT-III gas chromatograph-mass spectrometer, Varian Associates, Palo Alto, Calif., as described previously (11) .
Experimental design in vivo. (14) .
Fractionation of liver homogenates. All specimens of human liver were obtained at about 10:00 a.m. to minimize the diurnal variation of bile acid synthesis. The liver tissue was placed immediately in ice-cold 0.1 M Tris-Cl buffer, pH 7.4, which contained 2.5 mM EDTA, and was transported to the laboratory in an ice bath within 1 h. All subsequent operations were carried out at 4°C. The liver was extruded through a tissue press (Harvard Apparatus Co., Inc., Millis, Mass.). A 1-g aliquot was homogenized in a loose-fitting PotterElvehjem homogenizer with 4 ml of 0.1 M Tris-Cl buffer, pH 7.4, which contained 2.5 mM EDTA. The microsomal fraction was obtained by centrifuging the homogenate for 12 min at 20,000 g, followed by centrifugation at 100,000 g for 1 h (15). The microsomal pellet was washed by resuspension in 0.1 M Tris-Cl buffer, pH 7.4, with EDTA, followed by centrifugation for 1 h at 100,000 g. The final pellet was suspended in 0.1 M Tris-Cl buffer, pH 7.4, with EDTA in a volume corresponding to the original 20,000 g supernatant solution from which it had been prepared.
Protein was determined according to Lowry et al. (16) . The protein content of the microsomal fraction was about 5 mg/ml and, of the 100,000 g supernatant fraction, about 12 mg/ml.
Enzyme Assays
Conversion of 5f3-cholestane-3a,7a,12a-triol to 5/3-cholestane-3a,7a,12a,25-tetrol. The complete system contained in a volume of 1.0 ml: 85 mM phosphate buffer, pH 7.4, 1.7 mM MgCl2, 3 7a,12a,25-tetrol from the plate and measuring its radioactivity in a liquid scintillation counter. Because the specific radioactivity of the substrate was known, the radioactivity data could be expressed in terms of pmol of product formed.
To confirm the identity and the radioactive purity ofthe bio- '4C]cholic acid formed was isolated and its radioactivity was determined as described previously (7) .
RESULTS
In vivo conversion of 5f3-[7f3-3H]cholestane-3a, 7a,12a-triol to cholic acid. 5,3-[78_-3H]cholestane3a,7a,12a-triol (2 OCi) was injected intravenously to two control and two CTX subjects. The 3H-labeled cholic acid formed was isolated from daily specimens of bile collected over a period of 1 wk and its specific activity decay-curves were plotted as shown in Fig. 1 . In all subjects, radioactive cholic acid was detected within 1 d of pulse labeling. In the controls, maximum specific activity values were reached within 24 h, followed by a linear decay of the cholic acid specific activity curves. In contrast, the maximum specific activity of cholic acid in the CTX patients was reached only 2 d after pulse labeling and then declined linearly.
More detailed studies of the products formed from the labeled 5f3-cholestane-3a,7a,12a-triol showed the presence of 3H-labeled 5/3-cholestane-3a,7a,12a,25-tetrol in the bile specimens of the CTX patients; this labeled tetrol was absent in the bile of the control subjects. Fig. 2 illustrates the specific activity decay-curves of 5f3- [7,8-3H] cholestane-3a,7a,12a,25-tetrol and that of 3H-labeled cholic acid in one of the CTX patients (E.D.S.). The specific activity decay-curve of the tetrol intersected with the rising specific activity curve of cholic acid, thus showing a precursor-product relationship. Days after pulse labeling from all subjects (controls, as well as CTX patients) and the specific activity vs. time curves decayed exponentially, reaching a maximum within 24 h. In vitro conversion of 5f3-cholestane-3a,7a,12a-triol to cholic acid. To examine the individual steps on the pathway from 5,B-cholestane-3a,7a,12a-triol to cholic acid (Fig. 4) , the following reactions were carried out with labeled substrates: ( Table II and show that the enzyme activity catalyzing the 25-hydroxylation of 5f8-cholestane-3a,7a,12a-triol to yield 5,8-cholestane-3a,7a,12a,25-tetrol was active in both control and CTX subjects. In contrast, the transformation of 5,f-cholestane-3a,7a,12a,25-tetrol to were converted into cholic acid in both control and CTX subjects. In the control subjects, 5,8-cholestane3a,7a,12a-triol was rapidly transformed to cholic acid so that peak cholic acid specific activity was detected within the first 24 h after pulse labeling. In contrast, the specific activity of biliary cholic acid in the CTX subjects rose slowly over the first 24 h and did not reach a maximum value until 48 h after pulse labeling (Fig. 1) . When this transformation was examined more closely in one of the CTX subjects, a characteristic precursorproduct relationship between biliary cholic acid and 5,8-cholestane-3a,7a,12a,25-tetrol was observed (Fig.   2 ), which implies that most of the cholic acid originated from this tetrol (18) . Furthermore, no 5/3-cholestane3a,7a,12a-triol was detected in the bile of this CTX patient which suggests a rapid and complete conver- Days after pulse labeling FIGURE 3 Specific activity vs. time decay curves of cholic acid from bile of two normolipidemic and two CTX subjects after intravenous pulse labeling with 5f3[24-14C]3a,7a,12a, 24S,25-pentol.
cholic acid specific activities were reached within 24 h in both the CTX and control subjects; followed by similar exponential decay curves of radioactive cholic acid.
The results of the in vivo experiments (vide supra) indicate that in both CTX and control subjects there was no block in the formation of cholic acid from 5,8-cholestane-3a,7a, 12a,24S,25-pentol, whereas the transformation of 5,f-cholestane-3a,7a, 12a-triol to HO (17) and were found in the feces and bile of CTX subjects (11) , neither bile alcohol is converted to cholic acid (7). We postulate that both compounds accumulate in CTX subjects because deficient 24S-hydroxylation prolongs the exposure of 5,8-cholestane3a,7a,12a,25-tetrol to the microsomal 24R-and 23-hydroxylation systems. The block in bile acid synthesis may be related to the development of the clinical picture in CTX. Brain, tendon, and lung xanthomas and coronary atherosclerosis are the major clinical manifestations that result from the excessive deposition of cholesterol and cholestanol in these vital tissues. Recently, we have presented evidence that the increased, neutral sterol deposits result from the overproduction of both cholesterol and cholestanol (5) . However, because CTX is inherited as an autosomal recessive disease, the genetic defect should result from a single enzyme defect which must account directly or indirectly for all the clinical and biochemical aspects of this hereditary metabolic disease (19) . The demonstration that bile acid synthesis is abnormal with a specific defect in 24S-hydroxylation of 5,8-cholestane-3a,7a,12a,25-tetrol fits well into the definition of a recessively inherited genetic disease. As a result of diminished bile acid pool, cholesterol production increases; but, because of the block in side-chain cleavage, bile acid precursors are excreted and the augmented cholesterol production is only partially converted to bile acids. The remainder is available for deposition in the tissues and for cholestanol formation.
